Alto Neuroscience (ANRO) Debt to Equity (2023 - 2026)

Alto Neuroscience has disclosed Debt to Equity across 4 years of filings, most recently posting $0.07 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.07, down 54.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.07 (down 54.08% YoY), and the FY2025 annual result was $0.11, up 63.76% from the prior year.
• Debt to Equity came in at $0.07 for Q1 2026 at Alto Neuroscience, down from $0.11 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.18 in Q3 2025 to a low of -$0.14 in Q4 2023.
• The 4-year median for Debt to Equity is $0.07 (2026), against an average of $0.08.
• Across the five-year window, Debt to Equity jumped 195.94% in 2025 and slumped 54.08% in 2026, its largest moves.
• Alto Neuroscience's Debt to Equity stood at -$0.14 in 2023, then jumped by 149.21% to $0.07 in 2024, then jumped by 63.76% to $0.11 in 2025, then tumbled by 40.62% to $0.07 in 2026.
• The last three Debt to Equity figures came in at $0.07 (Q1 2026), $0.11 (Q4 2025), and $0.18 (Q3 2025), per Business Quant data.